Groundbreaking

Immunotherapy

We are a groundbreaking immunotherapy venture studio. We accelerate early-stage R&D discovery and build drug discovery programs to create companies that cure diseases from COVID to Cancer.

Arrow down

Reimagining

discovery

We are a groundbreaking immunotherapy venture studio. We accelerate early stage R/D discovery and build programs and companies, to cure diseases from COVID to Cancer.

Arrow down

Immunotherapy with Impact

Our studio of experienced, immunology-focused drug developers maximizes value creation by forming multiple, thematically aligned startups to develop and commercialize immunotherapeutics. We partner with university-based collaborators to extend novel and untapped fundamental biological observations, create proof-of-concept data, and generate advanced development candidate packages using our expertise and internal laboratories.

Bridging the “Therapeutic Valley of Death”

Novel immunotherapeutics face a formidable therapeutic valley of death. Successfully navigating this valley provides tremendous value to patients and investors – typically the largest step-up in a program’s lifetime.  We provide the neccessary R&D infrastructure to rapidly and effectively traverse this valley.

Foundery Innovations. Engineering Success. Validated efficacy. Validated safety. Validated developability.The valley of death. Poor success rate of novel observations and targets traversing to clinical assessment.Observation. Novel observation or target identification with potential therapeutic value. Limited valuation.Clinical drug 
development candidate. NewCo formation, 
or out-licensing. Large Step-up 
in valuation.Foundery Innovations. Engineering Success. Validated efficacy. Validated safety. Validated developability.

Our Team

Our studio was forged in 2021 by – Max, Michel, and Sriram – united by their shared goal to re-establish discovery as the basis for the next generation of immunotherapies.

With their deep knowledge of immunobiology and their impressive track record of discovering and developing multiple, multibillion-dollar immunotherapies, they have positioned Foundery to increase the efficiency and effectiveness of the pre-clinical R&D process.

They aim to preserve the innovative culture of biotech and bridge the translational gap by providing leading academic scientists with exclusive access to best-in-class technology platforms and the necessary R&D infrastructure to transform their discoveries into breakthrough therapies.

Executive Management Team

A Proven Record of Selecting and Developing Commercially Successful Therapies

Photo of Max Krummel

Max Krummel, Ph.D.

Founder &
Managing Member
  • UCSF Professor & Endowed Chair in Experimental Pathology
  • Discovered and patented Checkpoint Blockade Target CTLA-4 (2021 Yervoy Sales: $2B)
  • Defined Myeloid Tuning & founded Pionyr (Gilead secured $1.5B Buyout Option in 2020)
  • Discovered Immune Archetypes in Cancer & COVID
  • PhD, University California, Berkeley
View full bio
Logos
Photo of Michel Streuli

Michel Streuli, Ph.D.

Founder, Managing Member, &
Chief Executive Officer
  • Drove early development of multiple immunotherapies, including IntronA and Keytruda (2021 Keytruda Sales: $17B)
  • 20+ year biotech veteran
  • Former Professor at Harvard and Dana-Farber Cancer Institute
  • PhD, University of Zurich
View full bio
Logos
Photo of Venkataraman "Sriram"

Venkataraman “Sriram”, Ph.D.

Founder, Managing Member, &
Chief Scientific Officer
  • Guided preclinical pharmacology for Keytruda® and led Pionyr’s non-clinical PY314 program
  • 15+ years experience in immuno-oncology R&D and strategy development at Schering-Plough, Merck, Gilead and Pionyr
  • Expertise in small molecule and biologics development for immuno-oncology
  • PhD, University of Madras
View full bio
Logos
Photo of Jate Samathivathanachai

Jate Sam, MBA, CLP

Chief Business
Officer
  • Executed >$10B in M&A, financing, licensing transactions and ~$70M in PE/VC investments
  • 20 years of investment banking, corporate development, principal investing and general management experience in the biopharma and consumer sectors
  • MBA, Kellogg School of Management, Northwestern University
  • Certified Licensing Professional
View full bio
Logos

Contact Us

Interested in learning more? We're looking forward to hearing from you.

GET IN TOUCH
Foundery Innovations

our science

Electrophysiology and brain imaging data give network-level insight into neurodegenerative and psychiatric disease.

Brain diseases like Parkinson’s and Depression result in pathological network-level brain activity.

When our partners record this activity, we help them understand patient-specific pathophysiologies to guide treatment, uncover hidden disease phenotypes, and design better targeted therapies.

Brain data

our science

Time-series brain data requires time-series labels to generate the most insight.

We work with our partners to prospectively enrich electrophysiological and related time-series brain data with video data, audio data, and data from wearable sensors.

This makes it possible to analyze the evolution of neural state at fine time scales to discover new biomarkers for disease progression.

our science

Longitudinal and multi-patient analysis requires data aggregation.

We’ve automated the labeling, ingestion, and indexing of brain data at scale to create the largest ever aggregated datasets of these types.

With our software, our partners can collect and analyze real-world datasets without hassle, and clinical trial researchers optimize therapy parameters on a patient-by-patient basis.